 IRVINE, Calif.--BUSINESS WIRE--Axonics, Inc. Nasdaq: AXNX, Axonics, a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 4,025,000 shares of common stock at the public offering price of 50.00 per share, which includes the exercise in full by the underwriters of the underwriters option to purchase 525,000 additional shares at the public offering 